财务数据关键指标变化 - 公司2020年总运营费用为628.9万美元，较2019年的663.3万美元下降5.2%[247] - 研发费用2020年为194.4万美元，较2019年的223.8万美元减少29.4万美元（降幅13.1%）[248][250][251] - 公司持有无限制现金246.9万美元（2020年），较2019年183万美元增长35%[258] - 2020年衍生负债公允价值变动产生其他收入43.6万美元[256] - 2019年衍生负债公允价值变动产生其他收入973.5万美元[257] - 2020年利息支出70.6万美元，较2019年减少29.4万美元[256] - 截至2020年12月31日累计亏损3873.4万美元，营运资本187.7万美元[258] 融资与资本活动 - 2020年8月融资净收益608.6万美元[262] - 2021年1月至2月23日权证行权获得302万美元收益[264] - 信贷协议提供最高2000万美元融资额度，剩余可提取1355万美元[259] - 截至2019年12月31日，修订后信贷协议预付款项的公允价值为187.7938万美元[239] - 截至2019年12月31日，修订后信贷协议负债账面金额为38.707万美元[239] 研发合作与协议 - 2019年7月与StemoniX签署协议评估CBDVHS在癫痫模型中的应用[229] - 2019年2月与Purisys签署制造协议并支付预付款[230] - 2019年5月与密西西比大学签署修订协议将许可范围从眼部扩展至全领域[218] - 公司于2019年8月在澳大利亚成立子公司EMBI Australia以获取研发税收抵免[217] 研发进展与成果 - 2019年第二季度完成CBDVHS临床前实验显示其可穿透眼内多腔室[227] - 2019年12月StemoniX数据显示CBDVHS在抗癫痫活性上效力持续增强[231] - 2019年12月Glauconix数据显示CBDVHS具有显著抗炎和抗纤维化活性[226] - THCVHS首次人体研究从2020年下半年推迟至2021年第三季度[222] 持续经营风险 - 独立注册会计师对公司2020财年审计报告包含持续经营不确定性段落[269] - 公司2020年发生经常性运营亏损[269] - 审计机构对公司持续经营能力存在重大疑虑[269] - 财务报表编制基于持续经营假设[269] - 公司持续经营能力取决于未来实现盈利运营[269] - 公司持续经营能力取决于获得必要融资[269] - 财务报表未包含无法持续经营时的资产/负债调整[269] 表外安排与风险披露 - 无重大表外安排影响财务状[270] - 表外安排对投资者无重大财务影响[270] - 无市场风险定量定性披露要求[271]

10-Q 1 embi_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Emerald Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quart ...

10-Q 1 embi_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the transition period from ___________ to ___________ Commission File Number: 000-55136 Emerald Bioscience, Inc. (Exact name of registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ...

10-Q 1 embi_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Emerald Bioscience, Inc. (Exact name of registrant as specified in its ch ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-55136 Emerald Bioscience, Inc. (Exact name of registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from ___________ to ___________ FORM 10-Q Commission File Number: 000-55136 Emerald Bioscience, Inc. (Mark One) (Exact name of registrant as specified in its charter) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ___________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Emerald Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-55136 Emerald Bioscience, Inc. (Exact name of registrant as specified in its charter) Nevada 45-0692882 (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-55136 Nemus Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...